Open access
Open access
Powered by Google Translator Translator

Covid-19

Multiple early studies find notable Omicron vaccine evasion.

9 Dec, 2021 | 10:26h | UTC

Multiple early studies find notable Omicron vaccine evasion – CIDRAP

Related: A first, small study suggests Omicron is a larger threat to Covid-19 immunity than other variants.

 

Opinion: Why are we still isolating vaccinated people for 10 days?

9 Dec, 2021 | 10:24h | UTC

Why Are We Still Isolating Vaccinated People for 10 Days? – The Atlantic

 

[Preprint] Risk of Hospitalization, severe disease, and mortality due to COVID-19 in children with SARS-CoV-2 infection in Germany – “overall hospitalization rate associated with SARS-CoV-2 infection was 35.9 per 10,000 children, ICU admission rate was 1.7 per 10,000 and case fatality was 0.09 per 10,000”.

8 Dec, 2021 | 10:18h | UTC

Risk of Hospitalization, severe disease, and mortality due to COVID-19 and PIMS-TS in children with SARS-CoV-2 infection in Germany – medRxiv

Related:

Editorial: COVID-19 vaccines for children – “Although it is true that most children experience asymptomatic or mild disease, some will get quite sick, and a small number will die. It’s why children are vaccinated against influenza, meningitis, chickenpox, and hepatitis”.

Review: Should children under 12 years of age be vaccinated against COVID-19?

Deaths in children and young people in England after SARS-CoV-2 infection during the first pandemic year – “In total, 99.995% of children and young people with a positive SARS-CoV-2 test survived”.

 

WHO recommends against the use of convalescent plasma to treat COVID-19.

8 Dec, 2021 | 10:24h | UTC

News Release: WHO recommends against the use of convalescent plasma to treat COVID-19 – World Health Organization

See Guidance: WHO’s living guidelines on COVID-19 therapeutics

Infographic: A living WHO guideline on drugs for covid-19 – The BMJ

 

Commentary on Twitter (thread – click for more)

 

A first, small study suggests Omicron is a larger threat to Covid-19 immunity than other variants.

8 Dec, 2021 | 10:22h | UTC

A first, small study suggests Omicron is a larger threat to Covid-19 immunity than other variants – STAT

Original Study: SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection – medRxiv

 

Commentary from the author on Twitter (thread – click for more)

See also (thread – click for more)

 

RCT: In patients with severe Covid-19, high-flow oxygen therapy reduced the likelihood of invasive mechanical ventilation and decreased the time to clinical recovery compared to conventional oxygen therapy.

8 Dec, 2021 | 10:15h | UTC

Effect of High-Flow Oxygen Therapy vs Conventional Oxygen Therapy on Invasive Mechanical Ventilation and Clinical Recovery in Patients With Severe COVID-19: A Randomized Clinical Trial – JAMA

Related:

Non-invasive respiratory support in the management of acute COVID-19 pneumonia: considerations for clinical practice and priorities for research – “The two randomized controlled trials indicate superiority of non-invasive ventilation over high-flow nasal oxygen in reducing the need for intubation”.

[Preprint] RCT: non-invasive respiratory strategies in acute respiratory failure in patients with COVID-19 – CPAP reduced the composite outcome of intubation or death within 30 days; high-flow nasal oxygenation was not associated with better outcomes.

 

Phase 2 RCT: Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule.

8 Dec, 2021 | 10:12h | UTC

Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials – The Lancet Infectious Diseases

Invited Commentary: Booster doses for inactivated COVID-19 vaccines: if, when, and for whom – The Lancet Infectious Diseases

 

Video | COVID-19 Update: Omicron Variant.

8 Dec, 2021 | 10:09h | UTC

COVID-19 Update: Omicron Variant – JAMA

 

Beyond Omicron: what’s next for COVID’s viral evolution.

8 Dec, 2021 | 10:06h | UTC

Beyond Omicron: what’s next for COVID’s viral evolution – Nature

 

Editorial: Omicron is bad, but the global response is worse – “The pandemic will not end while vaccine equity keeps getting pushed to the margins”.

8 Dec, 2021 | 10:07h | UTC

Omicron is bad but the global response is worse – Nature

 

Case series with 139 adolescents and young adults with suspected myocarditis following mRNA vaccination showed most cases had a mild clinical course and rapid resolution of symptoms.

7 Dec, 2021 | 10:19h | UTC

Clinically Suspected Myocarditis Temporally Related to COVID-19 Vaccination in Adolescents and Young Adults – Circulation

News Release: Young people recover quickly from rare myocarditis side effect of COVID-19 vaccine – American Heart Association

 

Study shows increased immunogenicity of extended mRNA SARS-CoV-2 vaccine dosing intervals.

7 Dec, 2021 | 10:21h | UTC

Immunogenicity of Extended mRNA SARS-CoV-2 Vaccine Dosing Intervals – JAMA

 

Commentary on Twitter (thread – click for more)

 

The risk of postoperative complications following major elective surgery in active or resolved COVID-19 in the United States – Major, elective surgery 0–4 weeks after Covid-19 is associated with greatly increased risk of postoperative complications; surgery performed 4–8 weeks after infection is still associated with an increased risk of pneumonia.

7 Dec, 2021 | 10:23h | UTC

The Risk of Postoperative Complications following Major Elective Surgery in Active or Resolved COVID-19 in the United States – Annals of Surgery

Related:

Guideline: SARS‐CoV‐2 infection, COVID‐19 and timing of elective surgery

Study from 116 countries suggests surgery should be delayed for at least seven weeks following a COVID-19 diagnosis to reduce mortality risk

ASA Guidance: Preoperative testing for COVID-19 is essential, regardless of vaccination.

Position statement: Perioperative management of post-COVID-19 surgical patients.

Cohort study: Postoperative in-hospital mortality of patients with COVID-19 infection was more than double that in patients without COVID-19

 

The world has the tools to end the coronavirus pandemic. They’re not being used properly.

7 Dec, 2021 | 10:15h | UTC

The world has the tools to end the coronavirus pandemic. They’re not being used properly – CNN

 

Care of older people and people requiring palliative care with COVID-19: guidance from the Australian National COVID-19 Clinical Evidence Taskforce.

7 Dec, 2021 | 10:12h | UTC

Care of older people and people requiring palliative care with COVID-19: guidance from the Australian National COVID-19 Clinical Evidence Taskforce – Medical Journal of Australia

 

Perspective | ‘It’s misinformation at worst.’ Weak health studies can do more harm than good, scientists say.

7 Dec, 2021 | 10:17h | UTC

‘It’s misinformation at worst.’ Weak health studies can do more harm than good, scientists say – Science

 

Review of 4,470 cases of Multisystem Inflammatory Syndrome in Children in the US.

7 Dec, 2021 | 10:08h | UTC

Multisystem Inflammatory Syndrome in Children—United States, February 2020–July 2021 – Clinical Infectious Diseases

Related:

WHO issues guidelines on the treatment of children with multisystem inflammatory syndrome associated with COVID-19.

An Update on Multisystem Inflammatory Syndrome in Children Related to SARS-CoV-2.

Ten Things to Know About Multisystem Inflammatory Syndrome in Children (MIS-C).

Cohort study: long term follow-up showed most patients with post–COVID-19 Multisystem Inflammatory Syndrome in Children had good outcomes with no significant medium- or long-term sequelae.

Kawasaki Disease and Multisystem Inflammatory Syndrome in Children: An Overview and Comparison.

Cohort study: Six month follow-up of Multisystem Inflammatory Syndrome in Children.

Cohort study: Among children with Multisystem Inflammatory Syndrome (MIS-C) associated with Covid-19, there was no evidence that recovery differed after primary treatment with intravenous immune globulin (IVIG) alone, IVIG plus glucocorticoids, or glucocorticoids alone.

Cohort study: Among children with Multisystem Inflammatory Syndrome (MIS-C) associated with Covid-19, initial treatment with intravenous immune globulin (IVIG) plus glucocorticoids was associated with a lower risk of new or persistent cardiovascular dysfunction than IVIG alone.

Cohort study showed that the incidence of Multisystem Inflammatory Syndrome in Children (MIS-C) was 316 persons per 1 000 000 SARS-CoV-2 infections in persons younger than 21 years. The incidence was higher among Black, Hispanic or Latino, and Asian or Pacific Islander persons.

Cohort study showed good recovery for most children 6 months after Pediatric Inflammatory Multisystem Syndrome (PIMS-TS) associated with SARS-CoV-2.

Epidemiology of Multisystem Inflammatory Syndrome in Children: A Step Closer to Understanding Who, Where, and When

Neurologic involvement in children and adolescents with COVID-19 or Multisystem Inflammatory Syndrome

Clinical Update: Acute covid-19 and multisystem inflammatory syndrome in children

Differences in characteristics and outcomes of children and adolescents with Multisystem Inflammatory Syndrome in Children (MIS-C) vs. severe acute COVID-19

Cutaneous findings in SARS-CoV-2-associated Multisystem Inflammatory Disease in Children (MIS-C)

SR: Multisystem inflammatory syndrome in children related to COVID-19

Observational study: The combination of Immunoglobulins + Methylprednisolone was associated with a better course of fever compared to Immunoglobulins alone in Multisystem Inflammatory Syndrome in children

ACR Guidance for pediatric patients with multisystem inflammatory syndrome in children associated with SARS‐CoV‐2

New systematic review of Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 infection summarizes the clinical features, management, and outcomes of the disease, showing favorable outcomes for the majority of children

 

Six different COVID-19 boosters are safe and increase immunity when given after two doses of AstraZeneca or Pfizer-BioNTech, with significant variations in immune responses, UK trial shows.

5 Dec, 2021 | 23:57h | UTC

News Release: Six different COVID-19 boosters are safe and increase immunity when given after two doses of AstraZeneca or Pfizer-BioNTech, with large variations in immune responses, UK trial shows – The Lancet

Original Study: Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial – The Lancet

Commentaries:

Six different COVID-19 boosters induce variable immune response – CIDRAP

Covid booster shots significantly strengthen immunity, trial finds – The Guardian

Expert reaction to COV-BOOST study investigating safety and immunogenicity of seven COVID-19 vaccines as a third dose following two doses of either Oxford-AstraZeneca or Pfizer – Science Media Centre

 

Commentary on Twitter

 

European data on Omicron: Out of 109 cases confirmed so far, all cases for which there is available information on severity were either asymptomatic or mild.

5 Dec, 2021 | 23:50h | UTC

Epidemiological update: Omicron variant of concern (VOC) – data as of 3 December 2021 (12.00) – European Centre for Disease Prevention and Control

 

Commentary on Twitter:

 

Early data from South Africa hints Omicron variant may cause less severe Covid, but more research is needed.

5 Dec, 2021 | 23:51h | UTC

Early data from South Africa hints Omicron variant may cause less severe Covid, but more research is needed – STAT

Original report: Tshwane District Omicron Variant Patient Profile – Early Features

 

Fauci says early reports encouraging about omicron variant – “Thus far, it does not look like there’s a great degree of severity to it”.

5 Dec, 2021 | 23:47h | UTC

Fauci says Omicron variant doesn’t look severe, but ‘got to be careful’ – Associated Press

 

WHO has no reports yet of Omicron Covid deaths.

5 Dec, 2021 | 23:48h | UTC

WHO has no reports yet of Omicron Covid deaths – MedicalXpress

 

Commentary on Twitter

 

Editorial: Emergence of new SARS-CoV-2 Variant of Concern Omicron (B.1.1.529) – highlights Africa’s research capabilities, but exposes major knowledge gaps, inequities of vaccine distribution, inadequacies in global COVID-19 response and control efforts.

5 Dec, 2021 | 23:46h | UTC

Emergence of new SARS-CoV-2 Variant of Concern Omicron (B.1.1.529) – highlights Africa’s research capabilities, but exposes major knowledge gaps, inequities of vaccine distribution, inadequacies in global COVID-19 response and control efforts – International Journal of Infectious Diseases

 

[Preprint] Preliminary data points to increased risk of SARS-CoV-2 reinfection associated with the emergence of Omicron variant in South Africa.

3 Dec, 2021 | 10:29h | UTC

Increased risk of SARS-CoV-2 reinfection associated with emergence of the Omicron variant in South Africa – medRxiv

Commentaries:

Global Omicron COVID cases rise as evidence for immune escape grows – CIDRAP

Omicron seems to carry higher Covid reinfection risk, says South Africa – The Guardian

Reinfections three times more likely with Omicron: S. African research – MedicalXpress

 

Commentary from the author on Twitter (thread – click for more)

 

Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic.

3 Dec, 2021 | 10:28h | UTC

Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic – The Lancet

 

Commentary on Twitter

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.